Literature DB >> 10364651

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.

M Graefen1, J Noldus, U Pichlmeier, A Haese, P Hammerer, S Fernandez, S Conrad, R Henke, E Huland, H Huland.   

Abstract

OBJECTIVES: This study was undertaken to distinguish between patients who will and will not benefit from a retropubic radical prostatectomy (RRP) for clinically localized prostatic carcinoma (PCa) on the basis of preoperative and postoperative tumor characteristics.
METHODS: Data of 318 consecutive patients who underwent RRP for clinically localized PCa were reviewed. Preoperative characteristics used included clinical stage, findings on transrectal ultrasonography, prostate-specific antigen (PSA) values, Gleason grade, number of positive biopsies, number of biopsies containing any Gleason grade 4 and/or 5 cancer, and number of biopsies with predominant (>50% of cancerous tissue) Gleason grade 4 and/or 5 cancer. Postoperative characteristics included pathologic stage, Gleason grade, margin status, cancer volume, and volume of Gleason grade 4 and/or 5 cancer. The impact on biochemical relapse after RRP were calculated by Cox regression and CART (classification and regression tree) analysis to establish low, intermediate, and high risk of recurrence.
RESULTS: Of patients who underwent RRP, 66% showed no evidence of relapse after a follow-up of 42 months. All preoperative and postoperative characteristics showed a significant association with biochemical relapse. Cox regression of preoperative characteristics showed the number of positive biopsies with predominant Gleason grade 4 and/or 5 cancer to be the most accurate predictor of failure (p < 0.0001), followed by the number of positive biopsies and PSA. CART analysis distinguished between four risk groups on the basis of the same characteristics as in the Cox regression. The low-risk group consisted of 232 patients (75.1%) and the high-risk group of 17 patients (5.5%); corresponding Kaplan-Meier curves showed a 2-year PSA-free survival rate of 97% for the low-risk group and 20% for the high-risk group. Cox regression of postoperative characteristics recognized the volume of Gleason grade 4 and/or 5 as the characteristic with the strongest association with biochemical failure. CART analysis distinguished between four risk groups, using the volume of high-grade cancer as the most influential characteristic. The corresponding Kaplan-Meier curves showed for the low-risk group (n = 79; 29.6%) a PSA-free survival rate of 96% after 42 months and for the high-risk group (n = 47; 17.6%) a 21% PSA-free survival rate after 42 months.
CONCLUSION: For preoperative and postoperative estimation of biochemical recurrence after RRP, a quantitative analysis of high-grade cancer, expressed by the number of preoperative biopsy cores containing high-grade cancer and the volume of cancer, proved to be the best predictor of relapse. CART analysis might be useful in advising patients for their best therapy options. However, defined characteristics of risk groups should be evaluated with new prospective data before they are used routinely.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364651     DOI: 10.1159/000019922

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  13 in total

Review 1.  [Indications for and results of radical prostatectomy].

Authors:  M Graefen; P G Hammerer; A Haese; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

2.  Prognostic factors identifying biochemical recurrence in patients with positive margins after radical prostatectomy.

Authors:  Ioannis Anastasiou; Stavros I Tyritzis; Ioannis Adamakis; Dionysios Mitropoulos; Konstantinos G Stravodimos; Ioannis Katafigiotis; Antonios Balangas; Anastasios Kollias; Kitty Pavlakis; Constantinos A Constantinides
Journal:  Int Urol Nephrol       Date:  2010-10-30       Impact factor: 2.370

3.  Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.

Authors:  A M Luebke; T Schlomm; B Gunawan; H Bonkhoff; L Füzesi; A Erbersdobler
Journal:  Virchows Arch       Date:  2005-02-22       Impact factor: 4.064

4.  Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.

Authors:  Michael J Donovan; Faisal M Khan; Douglas Powell; Valentina Bayer-Zubek; Carlos Cordon-Cardo; Jose Costa; James Eastham; Peter Scardino
Journal:  BJU Int       Date:  2011-07-19       Impact factor: 5.588

5.  Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Tim Oliver; Henrik Møller; Victor Reuter; Peter Scardino; Jack Cuzick; Daniel M Berney
Journal:  Virchows Arch       Date:  2010-09-09       Impact factor: 4.064

6.  Experience with radical perineal prostatectomy in the treatment of localized prostate cancer.

Authors:  Evi Comploj; Armin Pycha
Journal:  Ther Adv Urol       Date:  2012-06

7.  An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy.

Authors:  Kristen L Zakian; Hedvig Hricak; Nicole Ishill; Victor E Reuter; Steven Eberhardt; Chaya S Moskowitz; Amita Shukla-Dave; Liang Wang; Peter T Scardino; James A Eastham; Jason A Koutcher
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

Review 8.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 9.  Adjuvant radiation therapy after radical prostatectomy: when is it indicated?

Authors:  Stephen M Graham; Jeffrey M Holzbeierlein
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

10.  Gene expression profiling predicts clinical outcome of prostate cancer.

Authors:  Gennadi V Glinsky; Anna B Glinskii; Andrew J Stephenson; Robert M Hoffman; William L Gerald
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.